Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 35Carcinoma, Hepatocellular 28Stomach Neoplasms 12Neoplasm Metastasis 12Nasopharyngeal Carcinoma 11Neoplasms 10Esophageal Neoplasms 10Melanoma 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 8Recurrence 7Lung Neoplasms 7Breast Neoplasms 7Biliary Tract Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Hyperthermia 3

Interventions

Radiotherapy 4Immune Checkpoint Inhibitors 4Oxaliplatin 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Advanced NSCLC × Immune Checkpoint Inhibitors × Clear all
NCT06751849 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06751901 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡